Skip to main content
Type at least 3 characters

40 articles

articles

Original Research

Published on 04 Jan 2024

Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial

in Therapy in Gastroenterology

  • Silvia Cruchet
  • Sandra Hirsch
  • Diana Villa-López
  • Mucio Moreno-Portillo
  • Juan C. Palomo
  • Ana T. Abreu-Abreu
  • Juan M. Abdo-Francis
  • Carlos Jiménez-Gutiérrez
  • Martin Rojano
  • Gabriel López-Velázquez
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1296048
  • 21,816 views
  • 5 citations

Original Research

Published on 23 Oct 2023

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

in Therapy in Gastroenterology

  • Giammarco Mocci
  • Arianna Cingolani
  • Giorgia Orrù
  • Carla Felice
  • Francesca Maria Onidi
  • Gianmarco Lombardi
  • Davide Checchin
  • Raffaele Colucci
  • Laurino Grossi
  • Antonio Ferronato
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1218228
  • 1,907 views
  • 1 citation